Mayflower Financial Advisors LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

Mayflower Financial Advisors LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,698 shares of the biopharmaceutical company’s stock after selling 3,590 shares during the period. Mayflower Financial Advisors LLC’s holdings in Pfizer were worth $1,212,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter worth about $26,000. Gladius Capital Management LP raised its position in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the last quarter. Quarry LP acquired a new position in shares of Pfizer in the second quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Pfizer in the third quarter valued at approximately $35,000. Finally, Joseph Group Capital Management raised its position in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Down 0.3 %

PFE opened at $26.79 on Wednesday. The stock has a market capitalization of $151.79 billion, a PE ratio of 36.20, a P/E/G ratio of 0.64 and a beta of 0.64. The firm’s fifty day moving average price is $26.15 and its 200 day moving average price is $27.92. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.17) earnings per share. As a group, research analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.42%. Pfizer’s dividend payout ratio is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.